Melhem, M.S.C.; Coelho, V.C.; Fonseca, C.A.; Oliveira, L.d.; Bonfietti, L.X.; Szeszs, M.W.; Magri, M.M.C.; Dorneles, F.S.; Taguchi, H.; Moreira, D.V.S.;
et al. Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillusfumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values. Pharmaceutics 2022, 14, 2161.
https://doi.org/10.3390/pharmaceutics14102161
AMA Style
Melhem MSC, Coelho VC, Fonseca CA, Oliveira Ld, Bonfietti LX, Szeszs MW, Magri MMC, Dorneles FS, Taguchi H, Moreira DVS,
et al. Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillusfumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values. Pharmaceutics. 2022; 14(10):2161.
https://doi.org/10.3390/pharmaceutics14102161
Chicago/Turabian Style
Melhem, Marcia S. C., Vivian C. Coelho, Claudia A. Fonseca, Lidiane de Oliveira, Lucas X. Bonfietti, Maria. W. Szeszs, Marcello M. C. Magri, Francine S. Dorneles, Hideaki Taguchi, Daniel V. S. Moreira,
and et al. 2022. "Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillusfumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values" Pharmaceutics 14, no. 10: 2161.
https://doi.org/10.3390/pharmaceutics14102161
APA Style
Melhem, M. S. C., Coelho, V. C., Fonseca, C. A., Oliveira, L. d., Bonfietti, L. X., Szeszs, M. W., Magri, M. M. C., Dorneles, F. S., Taguchi, H., Moreira, D. V. S., Motta, A. L., Batista, M. V., Kamei, K., & Shikanai-Yasuda, M. A.
(2022). Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillusfumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values. Pharmaceutics, 14(10), 2161.
https://doi.org/10.3390/pharmaceutics14102161
